Europe Allogeneic Human Chondrocyte Market, By Application (Osteoarthritis, Musculoskeletal System Disorders, and Others), By End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and By Country (Germany, U.K., France, Italy, Spain, Ru

Europe Allogeneic Human Chondrocyte Market, By Application (Osteoarthritis, Musculoskeletal System Disorders, and Others), By End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers), and By Country (Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Allogeneic human chondrocyte cell therapy is anticipated to be a good alternative to autologous chondrocyte implantation in the near future. Increasing product approvals by regulatory authorities is expected to fuel the market growth over the forecast period. For instance, in July 2017, Kolon TissueGene, Inc. received the South Korea Ministry of Food & Drug Safety (MFDS) for Invossa-K Inj. The product is currently available in the South Korean market and is marketed by Mundipharma and Kolon Pharmaceuticals.
Market Dynamics
Most of the pharmaceutical manufacturers operating in the Europe allogeneic human chondrocyte market are engaged in adoption of inorganic growth strategies such as collaborations, partnerships, and agreements to strengthen their market presence and expand its geographical footprint. In June, Kolon TissueGene, Inc., a manufacturer and developer of advanced cell and gene therapies, announced the extension of license agreement with Kolon Life Science, Inc., for the sales of Invossa-K Inj, a cell and gene therapy for knee osteoarthritis. The agreement is expected to expand the geographical footprint of Kolon Life Science, Inc. in the Middle East region with the grant of license for Saudi Arabia and United Arab Emirates (UAE) by the year 2024.
Key features of the study:
This report provides in-depth analysis of the Europe allogeneic human chondrocyte market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Europe allogeneic human chondrocyte market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Kolon TissueGene, Inc. and ISTO Technologies Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, type up-gradation, market expansion, and marketing tactics
The Europe allogeneic human chondrocyte market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe allogeneic human chondrocyte market
Detailed Segmentation:
Europe Allogeneic Human Chondrocyte Market, By Application:
Osteoarthritis
Musculoskeletal System Disorders
Others
Europe Allogeneic Human Chondrocyte Market, By End User:
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Europe Allogeneic Human Chondrocyte Market, By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Company Profiles
Kolon TissueGene, Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
ISTO Technologies Inc.
“*” marked represents similar segmentation in other categories in the respective section.